Breast Cancer Therapies: An Overview of Emerging Treatment Approaches, Clinical Trials, and Comorbidity Management

Abstract

Breast cancer is one of the most common cancers worldwide, with a significant burden on public health, accounting for a substantial number of diagnoses and deaths each year. The disease’s prevalence varies by geographical region, but it remains a leading cause of cancer-related mortality, especially in women. Current treatment approaches for breast cancer include surgery, chemotherapy, radiation therapy, hormone therapy, targeted therapies, and immunotherapy. These therapies have led to improved survival rates for many patients, particularly those with hormone receptor-positive (HR+) tumors. However, challenges persist, particularly for aggressive subtypes such as triple-negative breast cancer (TNBC), which remain difficult to treat with conventional therapies. Clinical trials continue to explore novel agents and combination therapies to improve outcomes, with a focus on precision medicine and personalized treatment strategies that consider the tumor’s molecular profile. Furthermore, comorbidities play a critical role in the management of breast cancer, as underlying health conditions can significantly impact treatment effectiveness and patient outcomes. Conditions such as diabetes, hypertension, cardiovascular disease, and obesity are common in breast cancer patients and can complicate treatment regimens, leading to adverse reactions or the need for adjustments in therapy. Diabetes can alter drug metabolism, reducing the effectiveness of chemotherapy and endocrine therapies. Cardiovascular conditions can limit the use of certain chemotherapies that have cardiotoxic side effects. The presence of autoimmune diseases or chronic pain can also affect treatment adherence and patient quality of life. Integrating care for comorbidities alongside cancer treatment is essential to ensure optimal outcomes, reduce treatment-related risks, and enhance the overall well-being of breast cancer patients.